ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen Chronische lymfatische leukemie (CLL) Richtlijnen en literatuur

Richtlijnen

Klik HIER voor de richtlijn 'Chronische lymfatische leukemie / kleincellig lymfocytair lymfoom' van de HOVON CLL werkgroep.

Literatuur

  1. Te Raa DG et al. Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. Leukemia & Lymphoma 2022. DOI: 10.1080 / 10428194.2022.2084731 
  2. Van Gelder M et al. Nieuwe eerstelijnsbehandelingen en behandeldoelen voor CLL in breder perspectief. Ned tijdschr Hematol 2023; 20:195-207
  3. Woyach JA et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018 Dec; 379:2517-28
  4. Fischer K et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019 June; 380:2225-2236
  5. Seymour JF et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018; 378:1107-20
  6. Gribben JG. How and when I do allogeneic transplant in CLL. Blood 2018; 132(1):31-39  
  7. Stephens DM How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood 2019; 133(12): 1298-1307
  8. Byrd JC et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 2021 Nov; 1; 39(31):3441-3452
  9. Thompson PA et al. Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up. Blood 2023; 142:21
  10. Brown JR et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. NEJM 2023: 388:4
  11. Kater AP et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM 2022; May 15
  12. Munir T et al. Chronic lymphocytic leukemia therapy guided by measurable residual disease. NEJM  2024; 390(4):326-337
  13. Eichhorst B et al. First-line venetoclax combinations in chronic lymphocytic leukemia. NEJM 2023; 388:1739-54 
  14. Kater AP et al. Fixed duration of venetoclax-rituximab in relapsed / refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clinic Oncol 2019; 37(4):269-277

 

Ga terug naar de CLL homepage of lees meer over CLL:

Ga terug naar de algemene homepage Behandelprotocollen.